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Abstract
Introduction: Radioiodine (131I) isotope therapy is the method of choice in the treatment of Graves’ disease relapse. The efficiency of this 
method is dependent on many factors; therefore, the present paper aims to identify the parameters that have a crucial impact on the 
efficacy of radioiodine therapy for Graves’ disease. 
Material and methods: The authors performed a retrospective analysis of the medical documentation of 700 Graves’ disease sufferers 
treated with131I. The patients were divided into three groups depending on the thyroid-absorbed dose of 131I: group I — 100 Gy, II — 150 
Gy, and III — 200 Gy. The authors assessed the influence of gender, age, presence of orbitopathy, TRab titres, thyroid mass, iodine uptake 
after 24 and 48 hours, and the absorbed dose on the treatment efficacy at one year post-131I administration. 
Results: The volume of thyroid gland (P < 0.002) and the thyroid-absorbed dose (P < 0.001) were the only factors that had a significant 
impact on the outcome of the treatment. The likelihood of hyperthyroidism persisting (odds ratio: 3.71, 95% confidence interval: 2.4–5.87) 
was greatest in patients from group I. In group II, with thyroid volume amounting both to 25 mL and to 25–50 mL, the percentage of 
hyperthyroidism was lowest (1 and 0%). However, with thyroid volume > 50 mL, the percentage of hyperthyroidism was lowest in 
group III (10%). 
Conclusions: The absorbed dose of 131I and the volume of the thyroid gland are two parameters that have a significant influence on the 
efficacy of radioiodine therapy for Graves’ disease. 150 Gy is the optimal dose for glands < 50 mL. A goitre > 50 mL requires an absorbed 
dose of 200 Gy in order to minimise the risk of recurrent hyperthyroidism. (Endokrynol Pol 2015; 66 (2): 126–131)
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Streszczenie 
Wstęp: Metodą z wyboru w leczeniu nawrotów choroby Gravesa-Basedowa jest terapia izotopowa radiojodem (131I). Efektywność tego 
leczenia zależy od wielu czynników, dlatego też celem pracy było wskazanie parametrów mających decydujący wpływ na skuteczności 
radiojodoterapii choroby Gravesa-Basedowa.
Materiał i metody: Przeanalizowano retrospektywnie dokumentację medyczną 700 pacjentów z chorobą Gravesa leczonych 131I. Ze wzglę-
du na dawkę pochłoniętą 131I w tarczycy, pacjentów podzielono na trzy grupy (grupa I — 100 Gy, II — 150 Gy, III — 200 Gy). Zbadano 
zależność płci, wieku, obecności orbitopatii, miana TRAb, masy tarczycy, jodochwytności tarczycy po 24 i 48 godzinach, dawki pochłoniętej 
na efektywność leczenia, po roku od podania 131I. 
Wyniki: Objętość tarczycy (P < 0,002), dawka pochłonięta w tarczycy (P < 0,001) miały jedynie istotny wpływ na wyniki terapii. Najwięk-
sze ryzyko utrzymywania się hipertyreozy (iloraz szans [OR] 3,71, 95% przedział ufności [CI] 2,4–5,87) wystąpiło u pacjentów z grupy I. 
W grupie II przy objętości tarczycy 25ml jak i 25-50ml odsetek hiperytreozy był najmniejszy (1 i 0%). Natomiast przy objętości tarczycy 
> 50 ml odsetek hipertyreozy był najmniejszy w grupie III (10%). 
Wnioski: Dawka pochłonięta 131I, objętość tarczycy to parametry mające istotny wpływ na skuteczności radiojodoterapii choroby Gra-
vesa-Basedowa. Optymalną dawką pochłoniętą w tarczycy z objętością < 50 ml jest 150Gy. Wole (> 50 ml) wymaga dawki pochłoniętej 
200Gy celem zminimalizowania nawrotu hipertyreozy. (Endokrynol Pol 2015; 66 (2): 126–131)
Słowa kluczowe: choroba Gravesa-Basedowa; radiojodoterapia; dawka pochłonięta
Introduction
The treatment of Graves’ disease (GD), which affects 
25 out of 100,000 people in Poland, involves using an-
tithyroid drugs for at least 1.5 years. If no remission is 
achieved, radical treatment methods are used, including 
surgery or, more frequently these days, radioiodine (131I) 
therapy. The to-date history of radioiodine treatment for 
GD justifies the claim that the radioisotope method is in-
expensive, relatively safe (in 3–15% of patients, it can ex-
acerbate the pre-existing orbitopathy), convenient (per 
os administration of, in most cases, one capsule of 131I), 
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non-invasive, and efficient (cures hypothyroidism after 
first course of treatment in 75–90% of cases) [1–3].
Nevertheless, there are several reasons for which 
the effects of treating Graves’ disease by means of ra-
dioiodine are less predictable than in the case of toxic 
goitre. First of all, it is an autoimmune disorder, in which 
hyperthyroidism is caused by antibodies acting against 
thyrocytes, and not by the gland itself. This makes the 
choice of correct therapeutic activity of radioiodine 
fairly difficult [4]. What is more, because of increased 
vascularisation and greater metabolic activity of thy-
rocytes in GD, the turnover of radioiodine is usually 
accelerated during treatment [5]. As a result, the effect 
of the 131I ionising radiation on thyrocytes is shorter, 
and this lowers the efficacy of radioiodine therapy. 
Treatment outcomes are also dependent on the volume 
of the thyroid gland [1, 6]. 
In view of the above, the authors undertook an at-
tempt to assess the efficiency of 131I therapy for Graves’ 
disease, on the basis of a retrospective analysis of medi-
cal documentation of patients treated at the Department 
of Nuclear Medicine of the University Clinic Hospital 
in Białystok in the years 2004–2014. 
Material and methods 
The sample comprised 700 GD patients, 524 of whom 
were women and 176 were men. The average age of 
the women and men was 50 ± 16 and 53 ± 18 years, 
respectively. All the subjects were administered 131I in 
order to eliminate hyperthyroidism, having previously 
undergone unsuccessful pharmacological treatment 
with thyrostatic drugs (for a period no shorter than 
1.5 years). Before the administration of therapeutic 131I, 
the patients had undergone routine eligibility screen-
ing, involving the assessment of standard clinical symp-
toms of Graves’ disease, biopsies of existing thyroid 
nodules (to rule out malignancy), USG of the thyroid 
and oculomotor muscles (if active orbitopathy was 
suspected), the estimation of TSH receptor antibodies 
(TRAb) via radioimmunoassay TRAK Human Brahms 
(norm < 2 IU/L), iodine uptake tests: 24-hour (T24) and 
48-hour (T48) ones, as well as thyroid scintigraphy with 
a gamma camera (NuclineTM Th, Mediso). 
The principle was assumed that the studied patients 
could commence treatment if their serum levels of free 
thyroxin (fT4), free triiodothyronine (fT3), and thyrotro-
pin (TSH) were within normal range, the 24-h iodine 
uptake in the thyroid was higher than 20%, and active 
orbitopathy had been excluded (after physical examina-
tion and oculomotor muscles USG). 
The therapeutic activity of 131I for each patient was 
calculated using Marinelli’s formula[7]: 
where: A — 131I therapeutic activity (MBq); 25 — unit 
conversion coefficient; m — volume of thyroid gland 
calculated from USG (mL); D — absorbed dose of 131I 
(Gy); T24 — 24-h
 131I uptake (%); Teff — effective 
131I half-
life in thyroid gland (days) = Tbiolog × Tphys/Tbiolog+ Tphys, 
where Tbiolog
 (rate of iodine excretion from the thyroid), 
Tphys (physical half-life of radioactive iodine).
The patients were divided into three groups ac-
cording to the thyroid-absorbed dose of 131I: group 
I — 100Gy, II — 150Gy, and III — 200Gy. The differ-
ences in the quantity of those doses resulted from the 
fact that patients were treated over a 10-years period, 
from 2004 until 2014, by various doctors, who adopted 
varied assumptions as to the thyroid-absorbed dose of 
radioiodine. 
 The calculated therapeutic activities of 131I 
were administered per os in the form of gel capsules. In 
Poland, the only available capsules are (MBq): 200, 280, 
400, 600, and 800. Whenever hyperthyroidism recurred 
after the first dose of radioiodine, an additional dose 
was not administered until after six months. 
 The efficacy of the treatment was expressed 
as the percentage of patients with euthyroidism, hy-
pothyroidism, or persistent hyperthyroidism within 
a year since radioiodine administration. 
The study was approved by the Ethics Committee 
for Medical Research, Medical University of Białystok, 
and is in accordance with the GCP (Good Clinical 
Practice). Informed consent was given by all patients 
participating in the study.
Statistical analysis
The statistical analysis of the results of the study was 
performed using the software package Statistica 10 (Stat 
Soft, Tulsa, USA). 
A one-way analysis of variance was applied to in-
vestigate the influence of gender, age, presence of orbi-
topathy, TRab titres, absorbed dose, as well as 24-hour 
and 48-hour iodine uptake on achieving euthyroidism, 
hypothyroidism, and persistent hyperthyroidism, using 
the c2 test for ordinal variables and the Mann-Whitney 
test for continuous variables. 
Additionally, a one-way analysis of variance helped 
to assess the relationship between thyroid volume and 
thyroid-absorbed dose of 131I and the attainment of eu-
thyroidism, hypothyroidism or hyperthyroidism after 
applied treatment. 
Moreover, the logistic regression function was used 
to evaluate the extent to which particular parameters 
A = 25 · m · DT24 · Teff
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contributed to the failure of treatment with 131I (persis-
tent hyperthyroidism). The regression analysis only 
took into consideration those parameters that were 
statistically significant for the outcome (P < 0.05). 
Results 
Table I includes the characteristics of the 700 Graves’ 
disease patients under study, with regard to clinical and 
physical parameters and the results of the treatment 
with 131I that they had undergone. The overall efficacy 
of the therapy at one year after 131I administration was 
as follows: euthyroidism was achieved in 31% of the 
subjects, hypothyroidism in 57%, while 12% of them 
experienced relapse or persistence of hyperthyroidism. 
The one-way analysis of variance demonstrated that 
the volume of the thyroid (P < 0.002) and the absorbed 
dose of radioiodine (P < 0.001) were significantly as-
sociated with an effective cure of hyperthyroidism. 
The highest percentage of hyperthyroidism (22%) was 
recorded among the patients with thyroid glands of 
> 50 mL, whereas the highest rate of euthyroidism 
(39%) was found in the group of patients whose gland 
volumes were 25–50 mL. The volume of the thyroid 
gland < 25 mL seemed to be associated with the highest 
rate of hypothyroidism and the lowest percentage of 
hyperthyroidism: 72% and 5%, respectively. 
With a thyroid-absorbed dose of 100 Gy, the propor-
tion of euthyroid (26%) and hypothyroid (49%) patients 
was the lowest. In those treated with 150 Gy and 200 
Gy, the percentage of euthyroidism and hypothyroid-
ism was higher and amounted to 37%, 52% and 34%, 
58%, respectively (Table I). 
It was shown, by means of a logistic regression 
model, that the likelihood of recurrent hyperthyroidism 
after 131I treatment was the highest (OR = 3.71) when 
the absorbed dose was 100 Gy and the thyroid volume 
exceeded 50 mL (OR = 3.52). The higher the absorbed 
dose, or the smaller the thyroid volume, the lesser the 
probability of hypothyroidism relapse. The lowest 
likelihood of persistence was noted in those patients 
whose thyroid volumes were below 25 mL and who 
had received absorbed doses of 200 Gy: OR = 1.1 or 
OR = 1.54 (Table II).
 Having analysed the interdependencies of the two 
parameters: absorbed dose and thyroid volume, and 
their impact on radioiodine therapy outcomes (Table III), 
one can conclude that in thyroids smaller than 25 mL, 
Table I. Characteristics of patients under study with regard to clinical and physical parameters and 131I therapy outcomes 
Tabela I. Charakterystyka badanych chorych z uwzględnieniem parametrów  klinicznych i fizycznych oraz wyników leczenia 131I
Hypothyroid Euthyroid Hyperthyroid P
No. of patients 399 (57%) 217 (31%) 84 (12%)
Sex 0.378
Female (n = 604) (56%) (31%) (13%)
Male (n = 96) (57%) (30%) (13%)
Age (years) 43.9 ± 14 46.6 ± 11,5 42.1 ± 13.2 0.094
Graves’ orbitopathy 0.142
Absence (n = 581) 57% 31% 12%
Presence (n = 119) 56% 32% 12%
TRAb, IU/L 12,8 ± 11,7 10,9 ± 14,8 11,7 ± 9,8 0.186
Thyroid volume [mL] < 0.002
< 25 (n = 220) 72% 23% 5%
25–50 (n = 390) 52% 39% 9%
> 50 (n = 90) 46% 32% 22%
Absorbed dose, Gy < 0.001
100 (n = 210 ) 49% 26% 25%
150 (n = 387 ) 52% 37% 11%
200 (n = 103 ) 58% 34% 8%
24-h Uptake (%) 54 ± 9 53 ± 7 55 ± 9 0.349
48-h Uptake (%) 53 ± 11 54 ± 9 52 ± 13 0.212
Teff. (days) 7,5 ± 0,7 7,1 ± 0,9 7,2 ± 0,8 0.087
n — number of patients
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hyperthyroidism did not recur provided that the ab-
sorbed dose was ≥ 150 Gy. Thyroid volumes of 25–50 
mL and absorbed doses of 150 Gy meant persistent 
hyperthyroidism in 2% of the subjects, similarly as 
with 200 Gy. Meanwhile, the percentage of euthyroid 
patients was higher in the group who had been given 
150 Gy (40%) than among those who had received 
200 Gy (35%). In thyroids smaller than 50 mL, the low-
est rate of recurrence was observed when the absorbed 
dose equalled 200 Gy (10% of hyperthyroidism). 
Discussion 
The history of 131I therapy for Graves’ disease dates back 
to 1940. Since then numerous scientific papers have 
been written on the subject. Consequently, a number 
of views, often markedly different, have come into 
being as regards the efficacy of radioiodine treatment, 
and more specifically as regards the parameters which 
influence its efficiency and the methods of calculating 
the therapeutic activity of 131I. 
Some authors focus on gender and age as the factors 
that determine the outcomes of radioiodine therapy for 
Graves’ disease [8, 9]. Allahabadia et al. claim that men 
have lower chances of recovery from hyperthyroidism 
than women (47% of men vs. 74% of women) without, 
however, providing an unequivocal explanation of this 
correlation. They also add, as do other authors, that 
the efficiency of treatment is lower in patients younger 
than 40 years old. This is because young people usually 
have larger goitres and higher blood concentrations of 
antithyroid antibodies (TRAb), which stimulate hyper-
thyroidism [10]. Our analysis shows, in accordance with 
what numerous other authors have found, that neither 
age (P < 0.094) nor gender (p < 0.378) have a significant 
influence on the outcomes of the therapy [11–13]. 
The volume of the thyroid can also have a consider-
able impact on the therapeutic effects of radioiodine. 
Markovic et al. used statistical analyses to prove that 
the chances of recovery are much higher for the pa-
tients whose thyroids are smaller than 62 g (only 9.6% 
of unsuccessful attempts) as opposed to persons with 
thyroids larger than 62 g (as many as 44% of cases of 
persistent hyperthyroidism) [14]. Our research has 
also proven that the volume of the thyroid gland has 
a significant (P < 0.002) bearing on the success of treat-
ment. The efficiency of therapy decreases along with 
the increasing size of the thyroid, particularly if the 
volume is considerably greater than 50 ml. Then the 
Table II. Logistic regression model with variables determining 
the probability of hyperthyroidism relapse at one year after 
administration of 131I
Tabela II. Model regresji logistycznej ze zmiennymi 
decydującymi o prawdopodobieństwie nawrotu nadczynności 
tarczycy po roku od podania 131I
Parameter OR 95% CI P
Thyroid volume [mL] 0.001
< 25 1.1 0,8–3,2
25–50 1.98 1.59–5.59
 > 50 3.52 2.94–5.12
Absorbed dose of 131I 0.001
In thyroid, Gy
100 3.71 2,4–5,87
150 1.84 1,36–5,38
200 1.54 0,2–3,75
Table III. Correlation between thyroid volume and absorbed dose of radioiodine and thyrometabolic state after treatment
Tabela III. Współzależność objętości tarczycy i dawki pochłoniętej radiojodu na stan tyreometaboliczny po zastosowanym leczeniu
Absorbed dose (Gy) Thyrometabolic state Thyroid volume [mL]
< 25 25–50 > 50
100 Euthyroid 16% 27% 21% 
Hypothyroid 83% 49% 37%
Hyperthyroid 1% 24% 42%
P < 0.001
150 Euthyroid 21% 40%  31%
Hypothyroid 79% 58%  48%
Hyperthyroid 0% 2%  21% 
P < 0.002
200 Euthyroid 9%  35% 39% 
Hypothyroid 91% 63% 51% 
Hyperthyroid 0% 2% 10% 
P < 0.001
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rate of hyperthyroidism is highest and amounts to 22%. 
Among the patients with thyroid volumes of 25–50 mL 
and below 25 mL, the recorded persistence of hyper-
thyroidism was 9% and 5%, respectively. This should 
be attributed to the fact that the larger the thyroid prior 
to the treatment, the more gland tissue remains intact 
after treatment with radioiodine, which increases the 
likelihood of persistent hyperthyroidism. 
Other authors also add that, besides its volume, the 
echogenicity of the thyroid gland can contribute to the 
differences in treatment outcomes. A hypoechogenic 
thyroid is more sensitive to ionising radiation than 
a normoechogenic one. This is associated with the fact 
that normoechogenic thyroids contain more colloid, 
which absorbs ionising radiation, thus weakening its 
destructive effect on cellular structures [15, 16]. 
In the examined population of patients, the outcome 
of the Graves’ disease radioiodine treatment was not 
correlated with the presence of orbitopathy as well as 
with the TRAb titres before the radioiodine administra-
tion. The above-stated conclusion remains in concord 
the results presented by other authors. [12–14, 24].
Among researchers into the treatment of Graves’ 
disease there is no agreement as to the method of cal-
culating the therapeutic activity of the radioisotope. 
Some authors use the old formula created by Marinelli, 
which takes into account the volume of the thyroid, its 
iodine uptake capacity, as well as the turnover of radi-
oiodine and its thyroid-absorbed dose [16–18]. Others 
recommend using an empirically established value of 
131I activity per one gram of thyroid tissue; and others 
apply fixed activities, often administered repeatedly at 
certain intervals, until effective [19–21]. These varying 
approaches to the calculation of therapeutic activity 
stem from the divergent assumptions concerning the 
thyroid function post-treatment. Ross believes that 
the therapeutic activity of radioiodine should be fixed: 
185MBq, 370MBq, or 555MBq, and that its applica-
tion should result in hypothyroidism [22]. A similar 
approach is adopted by the British Nuclear Medicine 
Society, which assures patients that precise computing 
of therapeutic activity using a formula does not translate 
into improved therapeutic outcomes, and thus recom-
mends fixed doses of radioiodine (from 400 to 600 MBq) 
[23]. The European Association of Nuclear Medicine, on 
the other hand, opts for Marinelli’s formula as a way to 
calculate the therapeutic activity of radioiodine and pre-
fers post-therapeutic euthyroidism to hyperthyroidism. 
To achieve such results in Graves’ disease treatment, it 
is crucial that the thyroid-absorbed dose of radioiodine 
used in the formula should be 150 Gy [6]. 
Our views on therapeutic activity calculation are 
largely the same as those expressed by the European 
Association of Nuclear Medicine. The only difference 
regards the amount of thyroid-absorbed dose of 131I. 
Our research has revealed that it is the volume of the 
thyroid that determines the absorbed dose. We have 
observed that for thyroids > 50 mL, the highest rate of 
success, including the attainment of euthyroid state, 
occurred when the absorbed dose was 200 Gy, whereas 
for thyroids < 50 mL, the optimum dose was 150 Gy. 
In the case of patients with thyroids of this volume 
(< 50 mL), a higher absorbed dose did not have any 
influence on overcoming hyperthyroidism, but merely 
increased the rate of hypothyroidism. This is because 
the smaller the volume of the gland, potentially the less 
gland tissue should be destroyed by ionising radiation 
used for anti-thyroid therapy. And, as is known from 
radiobiology, the destructive capability of ionising 
radiation is directly proportional to its tissue-absorbed 
dose. It should, moreover, be remembered that too small 
an absorbed dose of radioiodine significantly increases 
the risk of recurrent hyperthyroidism (in our study, the 
probability of relapse grew nearly four-fold, OR = 3.71, 
when the lowest dose of 100 Gy was administered). 
The literature also indicates the coefficient denoting 
the ratio between 131I uptake by the thyroid after 6 and 
24 hours as a parameter that has a significant impact on 
the efficacy of radioiodine therapy for Graves’ disease 
[24]. Isgoren et al. and Willegaignum et al. argue that 
with this coefficient at > 1 (> 0.9 according to the lat-
ter author), the rate of recurrence of hyperthyroidism 
reached 80% (83%). Meanwhile, when the coefficient 
was < 1 (< 0.9 according to Willegaignum et al.), the 
treatment failure rate dropped to 7% (17%) [20, 25]. 
The above coefficient, similarly to Teff. from Marinelli’s 
formula, expresses the turnover of radioactive iodine 
in the thyroid. In our study, Teff. did not have a sig-
nificant influence on treatment efficiency (P = 0.087). 
We account for this by the fact that when the thyroid-
absorbed dose of 131I is specified, the varying values 
of Teff. merely modify the activity of radioiodine that 
should be applied to achieve the intended therapeutic 
effect. Therefore, when the turnover of radioiodine 
in the thyroid is accelerated (Teff. is shortened), the 
therapeutic activity calculated by means of the formula 
increases accordingly; and, conversely, when Teff. is 
lengthened, it decreases. 
Conclusion 
The thyroid-absorbed dose of radioiodine and the vol-
ume of the gland are the key parameters that affect the 
efficacy of 131I therapy for Graves’ disease. For thyroids 
< 50 mL, 150 Gy is the optimum dose that ensures low 
risk of hyperthyroidism relapse (to 1%). Large goitres 
(> 50 mL) require an absorbed dose of 200 Gy so that the 
risk of relapse is minimised (OR = 1.54, 95% CI 0.2–3.75). 
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